Bladder Cancer Market by Type and Treatment - Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 170 Category: Pharma & Healthcare Report Code : HC095460
Bladder Cancer Market by Type (Invasive Bladder Cancer, Transitional Cell Carcinoma) Treatment (Chemotherapy, Immunotherapy, Radiation Therapy) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The bladder cancer market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Bladder cancer growth happens in the tissues of the bladder, which is the organ in the body that holds urine. There are various side effects that may demonstrate bladder cancer growth like fatigue, weight reduction, and bone delicacy, and these can show further developed illness. Bladder cancer occurs when unusual cells develop and duplicate rapidly and wildly, and attack different tissues. Types of bladder cancer includes urothelial carcinoma, squamous cell carcinoma and adenocarcinoma.
Drivers and Restraints
Increasing prevalence of bladder cancer drives the growth of bladder cancer market. Furthermore, drug innovations in the bladder cancer propels the growth of bladder cancer market. According to mayoclinic organization, bladder cancer is one of the most common cancers, affecting approximately 68,000 adults in the United States each year. Government initiatives and support for the treatment of bladder cancer fuels the growth of bladder cancer market. Increase in aging population, advancement in health care services, rising awareness regarding bladder diseases contribute to the growth of bladder cancer market. However, high cost of therapies may hamper the growth of bladder cancer market.
Regional Insights
Among the geographies, North America is expected to dominate the bladder cancer market. Improved healthcare infrastructure in the region contribute to the growth of bladder cancer market.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- AstraZeneca Plc.
- Merck & Co. Inc.
- GlaxoSmithKline Plc.
- Bristol-Myers Squibb Company
- Sanofi S.A.
- Celgene Corporation
- Pfizer Inc.
- Eli Lilly and Company
- Novartis International AG
- F. Hoffmann-La Roche AG
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Bladder Cancer Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Invasive Bladder Cancer
o Transitional Cell Carcinoma
o Bladder Cancer Market, By Treatment, Estimates and Forecast, 2017-2027 ($Million)
o Chemotherapy
o Immunotherapy
o Radiation Therapy
o Bladder Cancer Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o AstraZeneca Plc.
o Merck & Co. Inc.
o GlaxoSmithKline Plc.
o Bristol-Myers Squibb Company
o Sanofi S.A.
o Celgene Corporation
o Pfizer Inc.
o Eli Lilly and Company
o Novartis International AG
o F. Hoffmann-La Roche AG
o Bladder Cancer Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Bladder Cancer Market , By Country
o U.S. Bladder Cancer Market
o Canada Bladder Cancer Market
o Mexico Bladder Cancer Market
o Europe
§ Europe Bladder Cancer Market , By Country
o Germany Bladder Cancer Market
o UK Bladder Cancer Market
o France Bladder Cancer Market
o Russia Bladder Cancer Market
o Italy Bladder Cancer Market
o Rest of Europe Bladder Cancer Market
o Asia-Pacific
§ Asia-Pacific Bladder Cancer Market , By Country
o China Bladder Cancer Market
o Japan Bladder Cancer Market
o South Korea Bladder Cancer Market
o India Bladder Cancer Market
o Southeast Asia Bladder Cancer Market
o Rest of Asia-Pacific Bladder Cancer Market
o South America
§ South America Bladder Cancer Market , By Country
o Brazil Bladder Cancer Market
o Argentina Bladder Cancer Market
o Columbia Bladder Cancer Market
o Rest of South America Bladder Cancer Market
o Middle East and Africa
§ Middle East and Africa Bladder Cancer Market , By Country
o Saudi Arabia Bladder Cancer Market
o UAE Bladder Cancer Market
o Egypt Bladder Cancer Market
o Nigeria Bladder Cancer Market
o South Africa Bladder Cancer Market
o Rest of MEA Bladder Cancer Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Bladder Cancer Market, By Type
5.1. Introduction
5.2. Global Bladder Cancer Revenue and Market Share by Type (2017-2027)
5.2.1. Global Bladder Cancer Revenue and Revenue Share by Type (2017-2027)
5.3. Invasive Bladder Cancer
5.3.1. Global Invasive Bladder Cancer Revenue and Growth Rate (2017-2027)
5.4. Transitional Cell Carcinoma
5.4.1. Global Transitional Cell Carcinoma Revenue and Growth Rate (2017-2027)
6. Bladder Cancer Market, By Treatment
6.1. Introduction
6.2. Global Bladder Cancer Revenue and Market Share by Treatment (2017-2027)
6.2.1. Global Bladder Cancer Revenue and Revenue Share by Treatment (2017-2027)
6.3. Chemotherapy
6.3.1. Global Chemotherapy Revenue and Growth Rate (2017-2027)
6.4. Immunotherapy
6.4.1. Global Immunotherapy Revenue and Growth Rate (2017-2027)
6.5. Radiation Therapy
6.5.1. Global Radiation Therapy Revenue and Growth Rate (2017-2027)
7. Bladder Cancer Market, By Region
7.1. Introduction
7.2. Global Bladder Cancer Revenue and Market Share by Regions
7.2.1. Global Bladder Cancer Revenue by Regions (2017-2027)
7.3. North America Bladder Cancer by Countries
7.3.1. North America Bladder Cancer Revenue and Growth Rate (2017-2027)
7.3.2. North America Bladder Cancer Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Bladder Cancer by Countries
7.4.1. Europe Bladder Cancer Revenue and Growth Rate (2017-2027)
7.4.2. Europe Bladder Cancer Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Bladder Cancer by Countries
7.5.1. Asia-Pacific Bladder Cancer Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Bladder Cancer Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Bladder Cancer by Countries
7.6.1. South America Bladder Cancer Revenue and Growth Rate (2017-2027)
7.6.2. South America Bladder Cancer Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Bladder Cancer by Countries
7.7.1. Middle East and Africa Bladder Cancer Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Bladder Cancer Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. AstraZeneca Plc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Merck & Co. Inc.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. GlaxoSmithKline Plc.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Bristol-Myers Squibb Company
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Sanofi S.A.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Celgene Corporation
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Pfizer Inc.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Eli Lilly and Company
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Novartis International AG
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. F. Hoffmann-La Roche AG
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Bladder Cancer Market Forecast (2017-2027)
9.1. Global Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Bladder Cancer Market Forecast by Regions (2017-2027)
9.2.1. North America Bladder Cancer Market Forecast (2017-2027)
9.2.1.1. United States Bladder Cancer Market Forecast (2017-2027)
9.2.1.2. Canada Bladder Cancer Market Forecast (2017-2027)
9.2.1.3. Mexico Bladder Cancer Market Forecast (2017-2027)
9.2.2. Europe Bladder Cancer Market Forecast (2017-2027)
9.2.2.1. Germany Bladder Cancer Market Forecast (2017-2027)
9.2.2.2. France Bladder Cancer Market Forecast (2017-2027)
9.2.2.3. UK Bladder Cancer Market Forecast (2017-2027)
9.2.2.4. Russia Bladder Cancer Market Forecast (2017-2027)
9.2.2.5. Italy Bladder Cancer Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Bladder Cancer Market Forecast (2017-2027)
9.2.3. Asia-Pacific Bladder Cancer Market Forecast (2017-2027)
9.2.3.1. China Bladder Cancer Market Forecast (2017-2027)
9.2.3.2. Japan Bladder Cancer Market Forecast (2017-2027)
9.2.3.3. Korea Bladder Cancer Market Forecast (2017-2027)
9.2.3.4. India Bladder Cancer Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Bladder Cancer Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Bladder Cancer Market Forecast (2017-2027)
9.2.4. South America Bladder Cancer Market Forecast (2017-2027)
9.2.4.1. Brazil Bladder Cancer Market Forecast (2017-2027)
9.2.4.2. Argentina Bladder Cancer Market Forecast (2017-2027)
9.2.4.3. Columbia Bladder Cancer Market Forecast (2017-2027)
9.2.4.4. Rest of South America Bladder Cancer Market Forecast (2017-2027)
9.2.5. Middle East and Africa Bladder Cancer Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Bladder Cancer Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Bladder Cancer Market Forecast (2017-2027)
9.2.5.3. Egypt Bladder Cancer Market Forecast (2017-2027)
9.2.5.4. Nigeria Bladder Cancer Market Forecast (2017-2027)
9.2.5.5. South Africa Bladder Cancer Market Forecast (2017-2027)
9.2.5.6. Turkey Bladder Cancer Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Bladder Cancer Market Forecast (2017-2027)
9.3. Bladder Cancer Market Forecast by Type (2017-2027)
9.3.1. Bladder Cancer Forecast by Type (2017-2027)
9.3.2. Bladder Cancer Market Share Forecast by Type (2017-2027)
9.4. Bladder Cancer Market Forecast by Treatment (2017-2027)
9.4.1. Bladder Cancer Forecast by Treatment (2017-2027)
9.4.2. Bladder Cancer Market Share Forecast by Treatment (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Bladder Cancer Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Bladder Cancer Revenue and Revenue Share by Type (2017-2018)
Figure Global Invasive Bladder Cancer Revenue and Growth Rate (2017-2018)
Figure Global Transitional Cell Carcinoma Revenue and Growth Rate (2017-2018)
Table Global Bladder Cancer Revenue and Revenue Share by Treatment (2017-2018)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2018)
Figure Global Immunotherapy Revenue and Growth Rate (2017-2018)
Figure Global Radiation Therapy Revenue and Growth Rate (2017-2018)
Table Global Bladder Cancer Revenue by Regions (2017-2018)
Figure North America Bladder Cancer Growth Rate (2017-2018)
Figure North America Bladder Cancer Revenue and Growth Rate (2017-2018)
Figure North America Bladder Cancer by Countries (2017-2018)
Figure North America Bladder Cancer Revenue (Million USD) by Countries (2017-2018)
Figure United States Bladder Cancer Growth Rate (2017-2018)
Figure United States Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Bladder Cancer Growth Rate (2017-2018)
Figure Canada Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Bladder Cancer Growth Rate (2017-2018)
Figure Mexico Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Bladder Cancer Growth Rate (2017-2018)
Figure Europe Bladder Cancer Revenue and Growth Rate (2017-2018)
Figure Europe Bladder Cancer by Countries (2017-2018)
Figure Europe Bladder Cancer Revenue (Million USD) by Countries (2017-2018)
Figure Germany Bladder Cancer Growth Rate (2017-2018)
Figure Germany Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Bladder Cancer Growth Rate (2017-2018)
Figure France Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Bladder Cancer Growth Rate (2017-2018)
Figure UK Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Bladder Cancer Growth Rate (2017-2018)
Figure Russia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Bladder Cancer Growth Rate (2017-2018)
Figure Italy Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Bladder Cancer Growth Rate (2017-2018)
Figure Rest of Europe Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Bladder Cancer Growth Rate (2017-2018)
Figure Asia-Pacific Bladder Cancer Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Bladder Cancer by Countries (2017-2018)
Figure Asia-Pacific Bladder Cancer Revenue (Million USD) by Countries (2017-2018)
Figure China Bladder Cancer Growth Rate (2017-2018)
Figure China Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Bladder Cancer Growth Rate (2017-2018)
Figure Japan Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Bladder Cancer Growth Rate (2017-2018)
Figure Korea Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Bladder Cancer Growth Rate (2017-2018)
Figure India Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Bladder Cancer Growth Rate (2017-2018)
Figure Southeast Asia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Bladder Cancer Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Bladder Cancer Growth Rate (2017-2018)
Figure South America Bladder Cancer Revenue and Growth Rate (2017-2018)
Figure South America Bladder Cancer by Countries (2017-2018)
Figure South America Bladder Cancer Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Bladder Cancer Growth Rate (2017-2018)
Figure Brazil Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Bladder Cancer Growth Rate (2017-2018)
Figure Argentina Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Bladder Cancer Growth Rate (2017-2018)
Figure Columbia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Bladder Cancer Growth Rate (2017-2018)
Figure Rest of South America Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Bladder Cancer Growth Rate (2017-2018)
Figure Middle East and Africa Bladder Cancer Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Bladder Cancer by Countries (2017-2018)
Figure Middle East and Africa Bladder Cancer Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Bladder Cancer Growth Rate (2017-2018)
Figure Saudi Arabia Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Bladder Cancer Growth Rate (2017-2018)
Figure United Arab Emirates Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Bladder Cancer Growth Rate (2017-2018)
Figure Egypt Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Bladder Cancer Growth Rate (2017-2018)
Figure Nigeria Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Bladder Cancer Growth Rate (2017-2018)
Figure South Africa Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Bladder Cancer Growth Rate (2017-2018)
Figure Turkey Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Bladder Cancer Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Bladder Cancer Revenue (Millions USD) and Growth Rate (2017-2018)
Table AstraZeneca Plc. Bladder Cancer Financial Overview
Table Merck & Co. Inc. Bladder Cancer Financial Overview
Table GlaxoSmithKline Plc. Bladder Cancer Financial Overview
Table Bristol-Myers Squibb Company Bladder Cancer Financial Overview
Table Sanofi S.A. Bladder Cancer Financial Overview
Table Celgene Corporation Bladder Cancer Financial Overview
Table Pfizer Inc. Bladder Cancer Financial Overview
Table Eli Lilly and Company Bladder Cancer Financial Overview
Table Novartis International AG Bladder Cancer Financial Overview
Table F. Hoffmann-La Roche AG Bladder Cancer Financial Overview
Figure Global Bladder Cancer Revenue (Millions USD) and Growth Rate (2018-2025)
Table Bladder Cancer Market Forecast by Regions (2018-2025)
Figure North America Bladder Cancer Market Forecast (2018-2025)
Figure United States Bladder Cancer Market Forecast (2018-2025)
Figure Canada Bladder Cancer Market Forecast (2018-2025)
Figure Mexico Bladder Cancer Market Forecast (2018-2025)
Figure Europe Bladder Cancer Market Forecast (2018-2025)
Figure Germany Bladder Cancer Market Forecast (2018-2025)
Figure France Bladder Cancer Market Forecast (2018-2025)
Figure UK Bladder Cancer Market Forecast (2018-2025)
Figure Russia Bladder Cancer Market Forecast (2018-2025)
Figure Italy Bladder Cancer Market Forecast (2018-2025)
Figure Rest of Europe Bladder Cancer Market Forecast (2018-2025)
Figure Asia-Pacific Bladder Cancer Market Forecast (2018-2025)
Figure China Bladder Cancer Market Forecast (2018-2025)
Figure Japan Bladder Cancer Market Forecast (2018-2025)
Figure Korea Bladder Cancer Market Forecast (2018-2025)
Figure India Bladder Cancer Market Forecast (2018-2025)
Figure Southeast Asia Bladder Cancer Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Bladder Cancer Market Forecast (2018-2025)
Figure South America Bladder Cancer Market Forecast (2018-2025)
Figure Brazil Bladder Cancer Market Forecast (2018-2025)
Figure Argentina Bladder Cancer Market Forecast (2018-2025)
Figure Columbia Bladder Cancer Market Forecast (2018-2025)
Figure Rest of South America Bladder Cancer Market Forecast (2018-2025)
Figure Middle East and Africa Bladder Cancer Market Forecast (2018-2025)
Figure Saudi Arabia Bladder Cancer Market Forecast (2018-2025)
Figure United Arab Emirates Bladder Cancer Market Forecast (2018-2025)
Figure Egypt Bladder Cancer Market Forecast (2018-2025)
Figure Nigeria Bladder Cancer Market Forecast (2018-2025)
Figure South Africa Bladder Cancer Market Forecast (2018-2025)
Figure Turkey Bladder Cancer Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Bladder Cancer Market Forecast (2018-2025)
Figure Global Bladder Cancer Forecast by Type (2018-2025)
Figure Global Bladder Cancer Market Share Forecast by Type (2018-2025)
Figure Global Bladder Cancer Forecast by Type (2018-2025)
Figure Global Bladder Cancer Forecast by Treatment (2018-2025)
Figure Global Bladder Cancer Market Share Forecast by Treatment (2018-2025)
Figure Global Bladder Cancer Forecast by Treatment (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|